Kimberly Brue

Make the smart choice and register for this webinar!

6

Have you ever tried a "Yes ... and" exercise? In my recap of the Lab Manager Leadership Summit, I highlight tips from Stephanie Whitehead, MBA, MPH, MLS(ASCP) on how this exercise can build consensus during problem-solving. Today's Clinical Lab #clinicallab #problemsolving

19

1 Comment

Now that the FDA's final rule on LDTs is out (though not yet officially published), what's next for labs? Once they've finished reading and digesting all 528 pages of the final rule, regulatory experts Julie Ballard and Shannon Bennett will be sharing the highlights and outlining next steps for labs in our upcoming webinar, "Key Things Labs Need to Know about the FDA’s Final LDTs Rule." This one is our first-ever joint production with our colleagues at Today's Clinical Lab! If you've got any pressing questions, be sure to submit them upon registration. Join us live on May 30, or later on demand: https://lnkd.in/gyPCJCkY #FDA #LDTs #medicallaboratory #clinicallaboratory #IVDs

21

A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend? https://lnkd.in/ezX4Dsmb Citeline Commercial #biopharma #clinicaltrials #RnD

9

16July: How does Orum Therapeutics plan to replace chemo with the targeted conditioning agents for gene editing therapies that it will work to develop with Vertex Pharmaceuticals? Read about the collaboration in my latest for Genetic Engineering & Biotechnology News: https://lnkd.in/epKWDUbZ

14

While #ASCO24 is at an end, it was great following all of it on social media. If you were at ASCO and interested in potential collaborations with the journal Technology in Cancer Research & Treatment, please feel free to reach out. Thanks for sharing OncoDaily! #cancer #oncology #cancerresearch #oncodaily

5

Do you think you understand #PR? Think again. Check out the blog (link in post).

1

Can't wait to hear what these five experts have to say about the FDA budget progressing through the House right now; $355 million less than last year at a time when Congress is pressing the agency to do more with fewer resources! Also on the webinar agenda, discussions of: •       Enforcement trends/inspections •       Generics and biosimilars •       Supply chain issues and shortages •       Digital health technology •       Laboratory developed tests •       Accelerated approvals •       Advertising and promotion •       Rare diseases •       Expedited programs •       Clinical trial innovation •       Clinical trial diversity •       Cell and gene therapy •       OTC monographs •       Advisory committees It's a jam-packed program you can't afford to miss!

1

I have a few (more!) things to say on this topic: 1. I’ve found that many non-communicators (and sometimes, depending on your situation, that could be the whole rest of the org!) don’t grasp how much thought goes into something as seemingly simple as a bio. We approach every single thing we do with a strategic POV. 2. I have soo many pet peeves when it comes to bios. These couple in particular seem to come up all the time. I’m curious to hear what others think. - “...has or brings x years of experience” – Why is this necessary? To me, this is a crutch when someone’s personal brand hasn’t yet crystallized. If someone has a lot of great expertise, that should organically show up in how it’s all characterized in the bio itself. If including the number of years is a must (for ex: if someone looks junior but actually has more experience than meets the eye or if someone held a single job for a lot of years), then find another way to weave that in somewhere else into the bio.  - “...roles of increasing responsibility” – My understanding is that this phrase was originally coined to spare listing all of the person’s individual jobs. I’m sure there are times when it’s hard to get around using this phrase, but there are other ways to signal this. For example: “After achieving [name earlier job achievements or accolades], X became the [most senior title attained at company] and [was charged with, accomplished abc, etc.].”

6

1 Comment

With AI, Your results will certainly depend on your inputs. “Richness of language is the currency of generative AI.”

1

DNA analysis should be part of healthcare. Whole-genome sequencing can help make that possible for everyone — but we’re still not using the technology to its full potential to give people the power to anticipate their health risks. Even when people have access to whole-genome sequencing, the results are usually indecipherable, making it difficult for people to determine what their risks actually are. At Nucleus Genomics, we did two key things to solve this for our users: → Our reports translate the science behind your results. There’s little to no jargon — we write them to be understood and work with skilled designers on our visuals to break down the numbers. → We provide easy-to-print reports you can bring to your doctor. Doctors must know how DNA results can help their patients integrate whole-genome research into standard healthcare. I’m proud to work with a team that’s charting a new course for genomics to improve health for everyone, and thrilled that preorders are open. Here’s to a new chapter in healthcare!

22

1 Comment

🚧 Tired of research writing roadblocks?  Unleash the power of AI! 🤜🏻Don't let writer's block hold you back!  💫 AI tools can supercharge your workflow, but remember, they're for collaboration, not copy-pasting. 👩🏻‍💻 Here's your AI research toolkit: 📍 Scite: Citation analysis & research trends to build rock-solid arguments. 📍Semantic Scholar: Deep dives into your field with powerful search & exploration. 📍Consensus: ️ Refine your writing style for crystal-clear communication. 📍Smodin: Create impactful visuals that make your research shine. 💬 What are your favorite research-boosting AI tools? Let's hear them in the comments! #ai #research #researchwriting #researchstudent #network #learning #researchhacks #linkedin #linkedinforcreators #LIPostingchallenge

11

I want to remind everyone about the upcoming 2024 Philly Cell & Gene Therapy Conference. Don't miss the "Talk-To-An-Investor" session on June 15th from 2:40 PM to 4:45 PM at the Sheraton Valley Forge Hotel.   This is a fantastic opportunity to engage in 15-minute discussions with esteemed investors if you’re looking for RNA/ASO Tx angled funding.   💡My Session Highlights - June 15th: 1️⃣ Bioanalytical Strategies for In Vivo Quantification of Nucleic Acid Therapy 2️⃣ Delivery Challenges of Oligo Nucleotide Therapy 3️⃣ Model-Informed Drug Development for Nucleic Acid Therapy   At Rockland Immunochemicals, Inc., we're making significant advancements with our ModDetect™ panels. These panels are designed to facilitate the detection of specific chemical modifications independent of the sequence or location of the modification and can be used to evaluate a variety of RNA Tx modalities and nucleic acid structures. We’re collaborating with institutions to continue driving innovation in nucleic acid therapeutics. I would be happy to discuss opportunities with you and help connect you with the right people at the conference.   Looking forward to seeing you there!   #PhillyCGT #CellAndGeneTherapy #RNAtherapy #NucleicAcidTherapy #Biotech #Investors #RocklandImmunochemicals

33

#BigPharma companies like BMS, J&J and Pfizer are facing #patentcliffs that will put tens of billions of dollars in sales at risk between now and 2030. Here's how these #drugmakers are looking to offset some of the losses from upcoming #patentexpirations. https://lnkd.in/g2FD-M4D #pharma #pharmaceuticals

6

COTA and the FDA will advance #cancerresearch using #realworlddata, focusing on #regulatory decision-making and improving treatment evaluation and availability. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #healthdata

25

The recent developments in the AI industry have made one thing clear: AI is fundamentally controlled by Big Tech. Companies like Microsoft, Amazon, and Google not only provide the essential computing infrastructure but also dominate the market with their vast consumer reach and platform advantages. Here are some key considerations we should all discuss: Dependence on Big Tech: Startups and AI research labs rely heavily on the infrastructure and market reach of major tech firms. Market Control: Large tech companies shape the incentive structures and define the future of AI technology. Regulatory Challenges: Current government policies often entrench the power of these companies rather than mitigate it. Need for Transparency: There is a pressing need for aggressive transparency mandates to clear the opacity around data usage in AI training. Liability and Accountability: Companies should be required to meet baseline privacy, security, and bias standards before releasing AI products. Bold Regulation: To address market concentration, regulations should enforce business separation within the AI stack and prevent Big Tech from leveraging infrastructure dominance to consolidate their market position. As we witness the increasing assertiveness of Big Tech in protecting their market hold, it’s crucial to ask: Are we ready to implement robust accountability measures that prioritize public interest over corporate promises? #AI #accountability #technology #regulation

4

1 Comment

“In contrast to Game of Thrones, where individuals are making morally gray decisions to gain power or to survive as a house, here, it’s about the desire for individuals or groups of communities to survive as an entity to the next generation. So in many of the crises, it's about people making a decision and trading off between their ideals and their moral idealism versus the greater good, with the greater good being survival. This core instinct lays the framework for much of the game theory that underpins the later book. Machiavelli is correct, might makes right and the good is surviving. In these dark times, being kind to anybody is a massive privilege and a luxury. Idealism is fatal. As a result, when people don't play the rules of real politics, that's when the most lives are lost.” - Jeremy Au 区汉辉, Host of BRAVE Southeast Asia Tech Podcast Watch, listen or read the full insight at https://lnkd.in/gJUQPqw6 Nonton, dengar atau baca wawasan lengkapnya di https://lnkd.in/gEmn2eEh 观看、收听或阅读全文，请访问 https://lnkd.in/gYeS2mtV #SocialDarwinism #Technology #Community #VC #VentureCapital #TechnologyAdvancements #R&D #BRAVEpodcast

7

2 Comments

Today, BioPharma Dive published a database of patent expirations of 30 top selling drugs, tracking how long companies like AbbVie, Merck, Eli Lilly and Novo Nordisk can expect to protect multi-billion-dollar revenue streams. Do you know something about upcoming court decisions or patent-office filings that could change this picture? Please let us know! #biotech #pharmaceutical #patent #drugdevelopment

5